These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31103461)

  • 21. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interruption of Pacing Following Nonsustained Ventricular Tachycardia in an AAI Programmed Implantable Cardioverter Defibrillator.
    Egan P; Wilkoff BL; Tchou P
    Pacing Clin Electrophysiol; 2015 Sep; 38(9):1082-90. PubMed ID: 26010870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS).
    Burri H; Starck C; Auricchio A; Biffi M; Burri M; D'Avila A; Deharo JC; Glikson M; Israel C; Lau CP; Leclercq C; Love CJ; Nielsen JC; Vernooy K; ; Dagres N; Boveda S; Butter C; Marijon E; Braunschweig F; Mairesse GH; Gleva M; Defaye P; Zanon F; Lopez-Cabanillas N; Guerra JM; Vassilikos VP; Martins Oliveira M
    Europace; 2021 Jul; 23(7):983-1008. PubMed ID: 33878762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anesthesia care for subcutaneous implantable cardioverter/defibrillator placement: a single-center experience.
    Essandoh MK; Portillo JG; Weiss R; Otey AJ; Zuleta-Alarcon AN; Humeidan ML; Torres JL; Flores AS; Castellon-Larios K; Abdel-Rasoul M; Andritsos MJ; Perez WJ; Stein EJ; Turner KR; Dimitrova GT; Awad H; Bhandary SP; Tripathi RS; Joseph NC; Hummel JD; Augostini RS; Kalbfleisch SJ; Tyler JD; Houmsse M; Daoud EG
    J Clin Anesth; 2016 Jun; 31():53-9. PubMed ID: 27185678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitachycardia devices: realities and promises.
    Klein LS; Miles WM; Zipes DP
    J Am Coll Cardiol; 1991 Nov; 18(5):1349-62. PubMed ID: 1918713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter-Defibrillator Programming Diffuse Into Clinical Practice?
    Varma N; Jones P; Wold N; Cronin E; Stein K
    J Am Heart Assoc; 2019 Feb; 8(3):e007392. PubMed ID: 30712432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 32. Current implantable cardioverter-defibrillator programming in Europe: the results of the European Heart Rhythm Association survey.
    Proclemer A; Grazia Bongiorni M; Etsner H; Todd D; Sciaraffia E; Blomström-Lundqvist C;
    Europace; 2014 Jun; 16(6):935-8. PubMed ID: 24864305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defibrillators: Selecting the Right Device for the Right Patient.
    Al-Khatib SM; Friedman P; Ellenbogen KA
    Circulation; 2016 Nov; 134(18):1390-1404. PubMed ID: 27799257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.
    Silver MT; Sterns LD; Piccini JP; Joung B; Ching CK; Pickett RA; Rabinovich R; Liu S; Peterson BJ; Lexcen DR;
    Heart Rhythm; 2015 Mar; 12(3):545-553. PubMed ID: 25460168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Competitive athletes with implantable cardioverter-defibrillators-How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry.
    Olshansky B; Atteya G; Cannom D; Heidbuchel H; Saarel EV; Anfinsen OG; Cheng A; Gold MR; Müssigbrodt A; Patton KK; Saxon LA; Wilkoff BL; Willems R; Dziura J; Li F; Brandt C; Simone L; Wilhelm M; Lampert R
    Heart Rhythm; 2019 Apr; 16(4):581-587. PubMed ID: 30389442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).
    Healey JS; Hohnloser SH; Glikson M; Neuzner J; Mabo P; Vinolas X; Kautzner J; O'Hara G; VanErven L; Gadler F; Pogue J; Appl U; Gilkerson J; Pochet T; Stein KM; Merkely B; Chrolavicius S; Meeks B; Foldesi C; Thibault B; Connolly SJ;
    Lancet; 2015 Feb; 385(9970):785-91. PubMed ID: 25715991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD).
    Guerra F; Palmisano P; Dell'Era G; Ziacchi M; Ammendola E; Bonelli P; Patani F; Cupido C; Devecchi C; Accogli M; Occhetta E; Santangelo L; Biffi M; Boriani G; Capucci A;
    Heart Rhythm; 2016 Oct; 13(10):1987-92. PubMed ID: 27291511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in implantable cardioverter defibrillator therapy.
    Rickard J; Wilkoff BL
    Expert Rev Cardiovasc Ther; 2016; 14(3):291-9. PubMed ID: 26653411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.